Phaseline

Targets › SLC22A6

SLC22A6 (Solute carrier family 22 member 6): drug programs, companies and trials

3 programs from 3 companies in 3 trials: 2 Phase 2, 1 Phase 3; Neurology, Psychiatry; next expected readout May 2027.

Secondary active transporter that functions as a Na(+)-independent organic anion (OA)/dicarboxylate antiporter where the uptake of one molecule of OA into the cell is coupled with an efflux of one molecule of intracellular dicarboxylate such as 2-oxoglutarate or glutarate. Mediates the uptake of OA across the basolateral side of proximal tubule epithelial cells, thereby contributing to the renal elimination of…. (UniProt, Q4U2R8)

Open in Phaseline: the race on SLC22A6, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
University of MiamiProbenecid
Solute carrier family 22 member 6 inhibitor; Solute carrier family 22 member 8 inhibitor; Solute carrier family 22 member 11 inhibitor
SLC22A6, SLC22A8, SLC22A11Phase 3Infertility, MaleMay 2027
Fondation Ophtalmologique Adolphe de RothschildProbenecid
Solute carrier family 22 member 6 inhibitor; Solute carrier family 22 member 8 inhibitor; Solute carrier family 22 member 11 inhibitor
SLC22A6, SLC22A8, SLC22A11Phase 2Focal EpilepsySep 2029
Brown UniversityProbenecid
Solute carrier family 22 member 6 inhibitor; Solute carrier family 22 member 8 inhibitor; Solute carrier family 22 member 11 inhibitor
SLC22A6, SLC22A8, SLC22A11Phase 2Alcohol Use Disorder (AUD)Dec 2030

Conditions

Infertility, Male (1) Alcohol Use Disorder (AUD) (1) Focal Epilepsy (1)

Modalities

small molecule (3)

Companies

University of Miami (1) Brown University (1) Fondation Ophtalmologique Adolphe de Rothschild (1)

Related targets

SLC22A8 (3) SLC22A11 (3)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.